TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)

Part of paid clinical trials in New York, New York.

Sponsor
NYU Langone Health
Study ID
NCT07732010
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Dry Eye Disease (DED)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • TRYPTYR (Acoltremon ophthalmic solution 0.003%) — DRUG
    TRYPTYR will be administered one drop in each eye twice daily (once every 12 hours) for 30 days.

Study Details

The purpose of this research study is to determine the effectiveness of TRYPTYR as a treatment for Dry Eye Disease. The primary efficacy variable is change from baseline in the Ocular Surface Disease Index (OSDI) at week 2. The co-primary efficacy variables are change from baseline in the National Eye Institute (NEI) scale of the cornea and NEI scale of the conjunctiva at 1 month (the third visit).

Key Dates

First listed
Jul 28, 2026
Start date
Jul 6, 2026
Status verified
Jul 2026
Primary completion
Apr 20, 2027
Completion
May 25, 2027

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dry Eye Disease
    Participants will be treated with the TRYPTYR drug for one month

Primary Outcome Measure

Change in ocular surface disease index (OSDI) Score [ Time Frame: Baseline, Week 2 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
NYU Langone HealthNew YorkNew York10016-

Find similar trials in New York, NY

By research site
NYU Langone Health· New York, NY

Related Studies